No Active T

(**)**(11)(**)** 



PRODUCTE RESEARCH

INSIDE DELPHION

Search: Quick/Number Boolean Advanced Derwei

Tracking

Select.

## The Delphion Integrated View

Tools: Add to Work File: Create new Work I Buy Now: PDF | More choices... View: Expand Details | INPADOC | Jump to: Top Go to: Derwent ☑ Emai

> Title: WO9424297A1: DEFECTIVE RECOMBINANT ADENOVIRUSES FOR (

> > THERAPY OF TUMOURS [French]

Defective recombinant adenovirus contg. anticancer heterologous Derwent Title:

DNA - partic, tumour repressor gene, anti-sense gene or gene that

induces apoptosis, provides long lasting therapeutic effect.

[Derwent Record]

WO World Intellectual Property Organization (WIPO) Country:

A1 Publ.of the Int.Appl. with Int.search report i Kind:

Inventor: PERRICAUDET, Michel;

> HADDADA, Hedi; MAY, Evelyne;

Assignee: RHONE-POULENC RORER S.A.

PERRICAUDET, Michel

HADDADA, Hedi MAY, Evelyne

News, Profiles, Stocks and More about this company

1994-10-27 / 1994-04-15 Published / Filed:

> Application WO1994FR0000421

Number:

C12N 15/86; A61K 48/00; C12N 15/12; C12N 15/11; ☐ IPC Code:

C07K14/82; C12N15/861; ¿ECLA Code:

Priority Number: 1993-04-22 FR1993000004745

> Recombinant adenoviruses comprising a heterologous DNA Abstract:

sequence, preparation thereof, and use thereof for the treatment

and/or prevention of cancer. [French]

SINPADOC Show legal status actions Buy Now: Family Legal Status Report

Legal Status:

Expand description

AT AU BE CA CH DE DK ES FI FR GB GR HU IE IT JP LU MC NL Designated

NO NZ PT SE US Country:

Family: Show 17 known family members

Description

## + ADENOVIRUS RECOMBINANTS DEFECTIFS POUR LA THERAPIE GENIQUE DES TUMEURS

La présente invention concerne des vecteurs recombinants d'origine virale et leur utilisation pour le traitement des cancers. Plus particulièrement, elle concerne des adénovirus recombinants comportant une séquence d'ADN hétérologue dont l'expression dans une cellule se divisant anormalement permet d'inhiber au moins partiellement la division de ladite cellule. L'invention



concerne également la préparation de ces vecteurs et les compositions pharmaceutiques les contenant.

First Claim:

1.Adénovirus recombinant défectif contenant une Show all claims séquence d'ADN hétérologue dont l'expression dans une cellule cible permet d'inhiber au moins partiellement la division cellulaire. †

**ੰ** Forward References:

Go to Result Set: Forward references (33)

Buy PDF	Patent	Pub.Date	Inventor	Assignee	Title
À	US68058 <u>58</u>	2004-10-19	Zhang; Wei-Wei	Board of Regents, The University of Texas System	Methods for the adn of adenovirus p53
Y	US6 <u>79</u> 77 <u>0</u> 2	2004-09-28	Roth; Jack A.	Board of Regents, The University of Texas System	Methods and compo comprising DNA dat agents and P53
A	US6783980	2004-08-31	Fallaux; Frits Jacobus	Crucell Holland B.V.	Packaging systems recombinant adenovused in gene therap
À	US6747138	2004-06-08	Dixit; Vishva M.	Regents of the University of Michigan	Methods and comporegulating Fas-asso apoptosis
A	US6740320	2004-05-25	Zhang; Wei-Wei	Board of Regents, The University of Texas System	Recombinant P53 a methods and compo
A	<u>US6696423</u>	2004-02-24	Barsoum; James G.	Biogen, Inc.	Methods and comportherapies using generocoding secreted parties are the such as interferon-b
A	US6 <u>62718</u> 9	2003-09-30	Roth; Jack A.	Board of Regents, The University of Texas Systems	Inhibition of cellular proliferation using ra antisense molecules
À	US6602706	2003-08-05	Fallaux; Frits Jacobus	Introgene B.V.	Packaging systems recombinant adenoused in gene therap
À	US6562797	2003-05-13	Dixit; Vishva M.	The Regents of the University of Michigan	Methods and comporegulating FAS-assortations
A	US6511847	2003-01-28	Zhang; Wei-Wei	Board of Regents, The University of Texas System	Recombinant p53 a methods and compo
凶	US6482617	2002-11-19	Yeh; Patrice	Aventis Pharma S.A.	Viable contaminant adenoviruses, their and use
囚	US6482803	2002-11-19	Roth; Jack A.	Board of Regents, The University of Texas System	Modification of muta gene in tumors by re delivery of ribozyme
占	US6458578	2002-10-01	Brough; Douglas E.	GenVec, Inc.	Recombinant cell lir adenoviral gene pro

1					and DEF-A, and/or
Z	US6436700	2002-08-20	Roth; Jack A.	Board of Regents, The University of Texas Systems	Anti-sense p21 k-ra
A	US <u>6410029</u>	2002-06-25	Mukhopadhyay; Tapas	Board of Regents, The University of Texas System	2-methoxyestradiol- apoptosis in cancer
A	US <u>631</u> 29 <u>46</u>	2001-11-06	Yeh; Patrice	Rhone-Poulenc Rorer S.A.	Viable contaminant adenoviruses, their and use
A	<u>US6306652</u>	2001-10-23	Fallaux; Frits Jacobus	IntroGene B.V.	Packaging systems recombinant adenovused in gene therap
丛	<u>US6238893</u>	2001-05-29	Hoeben; Robert Cornelis	Introgene B.V.	Method for intracellu amplification
丛	US6210939	2001-04-03	Gregory; Richard J.	Canji, Inc.	Recombinant adence and methods of use
A	<u>US6200956</u>	2001-03-13	Scherman; Daniel	Aventis Pharma S.A.	Nucleic acid-contair composition, prepar use thereof
A	<u>US6143290</u>	2000-11-07	Zhang; Wei-Wei	The Board of Regents, University of Texas System	Tumor regression by adenovirus express type p53
兦	US6069134	2000-05-30	Roth; Jack A.	Board of Regents, The University of Texas System	Methods and compo comprising DNA dai agents and p53
	US6060238	2000-05-09	Dixit; Vishva M.	The Regents of the University of Michigan	Method and compos regulating apoptosis
兦	US6054467	2000-04-25	Gjerset; Ruth A.	Sidney Kimmel Cancer Center	Down-regulation of to enhance sensitivi mediated apoptosis
占	US <u>6046007</u>	2000-04-04	Dixit; Vishva M.	The Regents of the University of Michigan	Method and compositegulating apoptosis
À	US6017524	2000-01-25	Roth; Jack A.	Board of Regents, The University of Texas System	Inhibiting the growth deficient tumor cells administering the pt
	US60156 <u>65</u>	2000-01-18	Dixit; Vishva M.	The Regents of the University of Michigan	Method and compositegulating apoptosis
A	US599410 <u>6</u>	1999-11-30	Kovesdi; Imre	GenVec, Inc.	Stocks of recombina replication-deficient free of replication-con adenovirus
囚	US <u>5932210</u>	1999-08-03	Gregory; Richard J.	Canji Inc.	Recombinant adence and methods of use
A	US5824544	1998-10-20	Armentano; Donna	Genzyme Corporation	Adenovirus vectors therapy

A	US57 <u>47469</u>	1998-05-05	Roth; Jack A.	Regents, The	Methods and compo comprising DNA dai agents and p53
A	US5707618	1998-01-13	Armentano; Donna	Corporation	Adenovirus vectors therapy
À	US5637456	1997-06-10	Roth; Jack A.	The University of Texas, Board of Regents	Rapid test for deterr amount of functiona gene in a gene ther preparation

Other Abstract Info:

CHEMABS 122(09)098807D CHEMABS 122(09)098807D DERABS C1994-341876 DE C1994-341876









Nominate this for the Gall-



† Copyright © Univentio 2001-2003.

Copyright © 1997-2004 The Thomson Corporation

Subscriptions | Web Seminars | Privacy | Terms & Conditions | Site Map | Contact U